ResMed generated $5.5B in trailing twelve-month revenue, up 0.1% year-over-year. Net income was $1.5B with a 27.44% net margin. Gross margin stands at 61.59% and operating margin at 34.18%. Diluted EPS is $10.37, which grew 0.2% year-over-year. Based on the Q1 2026 filing.